Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal expects to meet or exceed 2025 guidance; net leverage seen at 3.6x

Positive Impact 3 of 5 guidance Written later

Amneal Pharmaceuticals said in a January 13, 2026 investor presentation filing that it expects to meet or exceed the 2025 full-year financial guidance it gave on October 30, 2025. It also estimates net leverage of about 3.6x as of December 31, 2025, down from 3.9x a year earlier. The filing reaffirms the existing guidance ranges rather than raising them, and the figures remain estimates subject to year-end close.

Key points

  • Guidance ranges unchanged from October 30, 2025: net revenue $3.0 billion to $3.1 billion and adjusted diluted EPS $0.75 to $0.80
  • Adjusted EBITDA guidance of $675 million to $685 million; operating cash flow guidance of $300 million to $330 million
  • Estimated net leverage of approximately 3.6x as of December 31, 2025, compared with 3.9x as of December 31, 2024
  • Figures are based on current estimates and remain subject to change until year- and quarter-end closing processes are complete

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECJan 13, 2026, 7:44 AM ET
Accession number0001723128-26-000003

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.